Product Program year 2021 Source: CMS Open Payments

Tacrolimus

Drug Immunology

NDC 45802-390-00

Open in the dashboard

General payments

$80,808

57 payments

Research payments

$298,112

8 payments

Through program year 2021, $80,808 in general payments and $298,112 in research payments were reported against Tacrolimus (Immunology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2021 Research $35,782 2
2020 General $39,383 11
2019 General $41,426 46
2019 Research $262,330 6

Breakdown

Who paid General payments · program years 2019–2020
  1. Astellas Pharma Inc $77,975 19 payments
  2. Astellas Pharma Global Development $2,480 1 payment
  3. Astellas Pharma US Inc $354 37 payments
Top recipients General payments · program year 2020
  1. Stanley Jordan Nephrology · West Hollywood, CA $36,903 94% · 10 payments
  2. Amer Zeidan Hematology & Oncology · New Haven, CT $2,480 6% · 1 payment

Each share is of general payments naming this product in 2020.

Specialties paid General payments · program year 2020
  1. Nephrology Internal Medicine $36,903 94% · 1 practitioner
  2. Hematology & Oncology Internal Medicine $2,480 6% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2020
  1. California $36,903 94% · 1 recipient
  2. Connecticut $2,480 6% · 1 recipient

Each share is of general payments naming this product in 2020 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

494,640

Prescriptions dispensed, refills included

Drug cost

$77,044,280

Paid at the pharmacy, in all

Medicare Part D drugs matched to TACROLIMUS, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Tacrolimus Same name 13,295 478,838 $64,280,611
Envarsus Xr Tacrolimus Same name 548 13,324 $11,012,408
Prograf Tacrolimus Same name 120 2,229 $1,554,097
Astagraf Xl Tacrolimus Same name 16 249 $197,163

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 277 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Meagan Reynolds Nurse Practitioner OH 1,379 $154,473 None on record
John Goss General Surgery TX 1,281 $168,133 None on record
Navid Ezra Dermatology CA 1,195 $470,520 None on record
Jessica Siudowski Nurse Practitioner OH 1,159 $199,642 None on record
Michaela Elliott Physician Assistant MN 1,126 $150,133 No profile

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 277 with Patron
57 general · 8 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record